Schering Corporation

Other

Merck Sharp + Dohme Corp.

Hung V Le

Paul Reichert

Paul P Trotta

Vincent Stewart Madison

Tattanahalli L Nagabhushan

Gerald S Hammond

Shahriar Shane Taremi

Thomas E Hesson

Anthony F Mannarino

Corey Strickland

Gerald Wayne Shipps, Jr

Li Xiao

Yaolin Wang

Rumin Zhang

Nicholas J Murgolo

Paul J Zavodny

Jose S Duca

Richard N Ingram

Bruce A Malcolm

Winifred W Prosise

Barbara Dalie

Stephen Tindall

Wenyan Wang

Yao Ma

Kenneth Miller

Jun Zou

Robert Palermo

Boris Feld

Hanh Nguyen

Xiao Tong

Jian-Jun Liu

Tin-Yau Chan

Thierry Olivier Fischmann

Brian M Beyer

Andrew Joseph Prongay

Gail F Seelig

Krishna Kalghatgi

Lata Ramanathan

Todd W Mayhood

Catherine Smith

Jennifer Joanne Gesell

Robert A Kosecki

Michael R Ziebell

T L Nagabhushan

The present invention provides, inter alia, crystals of the MEK1 polypeptide which are particularly useful for structure based drug design as well as methods of use thereof.

MEK1 polypeptides

The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.

Assay for PCSK9 inhibitors

The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.

HDM2 polypeptides

The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.

Treatments for Flaviviridae virus infection

HDM2 Polypeptides

[object Object]

The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

Catalytic domain of ADAM33 and methods of use thereof

Humanized monoclonal antibodies against human interleukin-4

Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.

Cloning and exprssion of humanized monoclonal antibodies against human

A method for making crystals of zinc interferon alpha-2, and the use thereof in depot formulations, are disclosed.

Method for preparing zinc interferon alpha-2 crystals

Polypeptide inhibitors of gamma interferon

This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.

Crystalline r-h-GM-CSF and method

A process for crystallizing recombinant human interleukin 4 (rhulL-4) from a solution containing a sulfate or citrate salt is described. The crystalline form is suitable for x-ray diffraction and has wide applications in several pharmaceutical processes including purification, formulation and manufacturing.

Crystalline interleukin-4

Method for preparing interferon alpha-2 crystals

Growing community of inventors

Rockaway, NJ, United States of America

Hung V Le